Ticagrelor Global Market Report 2025

The ticagrelor market size has grown strongly in recent years. It will grow from $1.79 billion in 2024 to $1.93 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%.

This historical growth can be linked to factors such as the rising burden of cardiovascular conditions, an aging global population, increased public awareness regarding heart health, advancements in pharmaceutical R&D, and the growing incidence of acute coronary syndrome.

The ticagrelor market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%.

Key drivers of this projected growth include the increasing integration of personalized treatment approaches, surging healthcare spending, rising preference for less invasive therapies, a greater emphasis on preventive cardiac care, and supportive governmental cardiac health programs. Notable trends expected during the forecast period include advances in personalized medicine, the emergence of generic ticagrelor products, the use of AI in drug development, innovations in antiplatelet therapy, and the push for improved patient adherence through fixed-dose combination medications.

The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the ticagrelor market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease, heart failure, stroke, and hypertension. This growing prevalence is largely attributed to unhealthy dietary habits, including excessive intake of saturated fats, trans fats, added sugars, and sodium, which contribute to high blood pressure, obesity, and elevated cholesterol levels - key risk factors for heart-related conditions. Ticagrelor plays a crucial role in treating these diseases by preventing platelet aggregation, thereby reducing the risk of blood clots. It enhances patient outcomes by lowering the likelihood of heart attacks and strokes, particularly in high-risk populations. For example, in January 2024, the American Heart Association, a US-based nonprofit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2022, reflecting a 4% rise from 224.4 per 100,000 in 2021. Consequently, the increasing burden of cardiovascular diseases is supporting the expansion of the ticagrelor market.

Key players in the ticagrelor market are actively pursuing regulatory approvals to broaden product indications, improve market penetration, and enhance their competitive standing. Regulatory approvals signify official authorization from governmental bodies to market and distribute a product, ensuring it adheres to established safety, efficacy, and quality standards. For example, in May 2025, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical firm, secured an abbreviated new drug application (ANDA) from the US Food & Drug Administration (USFDA) for its generic ticagrelor tablets in 90 mg strength, along with tentative approval for the 60 mg variant. These tablets are intended to lower the risk of cardiovascular events by inhibiting platelet aggregation and preventing the formation of blood clots.

In May 2023, SERB Pharmaceuticals, a pharmaceutical company based in Luxembourg, entered into a partnership with SFJ Pharmaceuticals Inc. to further the development of a ticagrelor reversal agent. This collaboration aims to support the development, obtain U.S. regulatory approval, and commercialize bentracimab - a reversal agent designed to rapidly neutralize the blood-thinning effects of ticagrelor in patients who require emergency surgery or are experiencing severe bleeding. SFJ Pharmaceuticals Inc. is a U.S.-based pharmaceutical company that specializes in developing ticagrelor reversal agents.

Major players in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., and PhaseBio Pharmaceuticals Inc.

Ticagrelor is an oral antiplatelet drug primarily prescribed to lower the risk of heart attacks, strokes, and other cardiovascular complications in patients with acute coronary syndrome (ACS) or a prior myocardial infarction. It functions by preventing platelet aggregation, which helps reduce the formation of blood clots in the arteries. This enhances blood circulation and decreases the chances of additional cardiovascular incidents.

Ticagrelor is available mainly in two dosage forms: 90 mg and 60 mg tablets. The 90 mg formulation is typically used under prescription to prevent clot formation in individuals diagnosed with acute coronary syndrome or those with a previous heart attack. It falls under multiple therapeutic classes, including antiplatelet and antithrombotic agents. The drug is distributed through various channels such as hospital pharmacies, retail pharmacies, and online platforms. Its primary therapeutic applications include managing acute coronary syndrome, treating myocardial infarction, preventing strokes, and other related conditions. Ticagrelor is used across diverse healthcare settings, including hospitals, clinics, ambulatory care centers, and others.

The ticagrelor market research report is one of a series of new reports that provides ticagrelor market statistics, including ticagrelor industry global market size, regional shares, competitors with a ticagrelor market share, detailed ticagrelor market segments, market trends and opportunities, and any further data you may need to thrive in the ticagrelor industry. This ticagrelor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the ticagrelor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ticagrelor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ticagrelor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ticagrelor market consists of sales of branded oral tablets, generic ticagrelor formulations, fixed-dose combination products, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.